OncoMatch/Clinical Trials/NCT05331105

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Is NCT05331105 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies HL-085 for neurofibromatosis 1.

Phase 2RecruitingShanghai Kechow Pharma, Inc.NCT05331105Data as of Jun 2026Location: China

Treatment: HL-085 — This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

HL-085

Biomarker criteria

Required: NF1 mutation

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≤ 80

Prior therapy

Cannot have received: MEK inhibitor

Prior treatment with MEK 1/2 inhibitors

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05331105 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior MEK inhibitor disqualifies patients from enrollment.

Does this trial require NF1?

Yes, NF1 mutation is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 80 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify